Engineering the Future
in targeted cancer therapy
ImmuVia is developing novel antibody-based targeted therapeutics to treat oncological diseases.
Anti-MUC16 Humanized IgG1
Binds to MUC16 Tumor Antigen
Anti-DR5 Fully Human scFv
Binds to Death Receptor 5
Targeting tumors with high unmet medical need
Our aim is to improve efficacy, while avoiding toxicity
Our agents are designed to eradicate tumors effectively & selectively – not harming healthy tissues
Unlike conventional chemotherapeutic agents and antibody-drug conjugates, ImmuVia discovers and develops new medicines that do not contain compounds that are toxic for the patients
Unlike immuno-oncology treatments, which often provoke patients' immune system to cause side effects, ImmuVia's agents do not interfere with the immune system
ImmuVia uses its hard-won insights to develop innovative biologics
Selective Targeting Technology
Flagship Drug Candidate IMV-M™
Two arms recognize a cancer cell via a tumor-associated antigen, MUC16
Multiple IMV-M™ molecules bind to a single MUC16
Two arms target death receptor 5 (DR5)
MUC16 clustering enforces clustering of DR5
Clustering triggers DR5 activation, initiating apoptosis (programmed cell death)
Selective Targeting Technology: Universal
Building on the discovery of IMV-M™, ImmuVia developed a universal selective targeting platform that creates recombinant antibody-based agents
These agents bind to a clinically validated tumor-associated antigen and powerfully trigger apoptosis—selectively and effectively—in target cells
Our Science
Leveraging decades of experience, our team has identified high-value targets and developed biologic agents for effective eradiation of malignant cells.